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Background: MYH9-related disease (MYH9-RD) is a rare syndromic disorder deriving from mutations in MYH9, the
gene for the heavy chain of non-muscle myosin IIA. Patients present with congenital thrombocytopenia and giant
platelets and have a variable risk of developing sensorineural deafness, kidney damage, presenile cataract, and liver
abnormalities. Almost all MYH9-RD patients develop the hearing defect, which, in many individuals, progresses to
severe to profound deafness with high impact on quality of life. These patients are potential candidates for cochlear
implantation (CI), however, no consistent data are available about the risk to benefit ratio of CI in MYH9-RD. The
only reported patient who received CI experienced perisurgery complications that have been attributed to concurrent
platelet defects and/or MYH9 protein dysfunction.
Methods: By international co-operative study, we report the clinical outcome of 10 patients with MYH9-RD and severe
to profound deafness who received a CI at 8 institutions.
Results: Nine patients benefited from CI: in particular, eight of them obtained excellent performances with restoration
of a practically normal hearing function and verbal communication abilities. One patient had a slightly worse
performance that could be explained by the very long duration of severe deafness before CI. Finally, one patient
did not significantly benefit from CI. No adverse events attributable to MYH9-RD syndrome were observed, in
particular no perisurgery bleeding complications due to the platelet defects were seen. Patients’ perioperative
management is described and discussed.
Conclusions: CI is safe and effective in most patients with MYH9-RD and severe to profound deafness and should
be offered to these subjects, possibly as soon as they develop the criteria for candidacy.
Keywords: MYH9-related disease, Genetic deafness, Inherited thrombocytopenia, Cochlear implantation, Fetchner
syndrome, Epstein syndrome, May-Hegglin anomaly, Non-muscle myosinBackground
MYH9-related disease (MYH9-RD) is an autosomal-
dominant syndromic disorder deriving from mutations
in MYH9, the gene for the heavy chain of non-muscle
myosin IIA (NMMHC-IIA) [1,2]. MYH9-RD is charac-
terized by a complex phenotype. All patients present at
birth with thrombocytopenia, platelet macrocytosis, and
pathognomonic cytoplasmic inclusions of the mutant pro-
tein in leukocytes; most of them subsequently develop sen-
sorineural hearing loss, proteinuric nephropathy, presenile* Correspondence: alessandro.pecci@unipv.it
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unless otherwise stated.cataract, and/or alterations of liver enzymes [3,4]. MYH9-
RD encompasses four syndromes that have been consid-
ered for many years as distinct disorders, May-Hegglin
Anomaly (MHA, MIM 155100), Sebastian syndrome (SBS,
MIM 605249), Fechtner syndrome (FTNS, MIM 153640),
and Epstein syndrome (EPTS, MIM 153650). The identifi-
cation of MYH9 as the gene responsible for all of these
syndromes led to demonstration that MHA, SBS, FTNS,
and EPTS actually represented different clinical presen-
tations of the same condition, for which the definition
of MYH9-RD has been introduced [5-7].
Sensorineural hearing loss is the most frequent non-
congenital manifestation of the MYH9-RD. A recent ana-
lysis of 255 patients showed that deafness was present intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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35 years, and was expected to develop over time in almost
all cases [8]. The severity of hearing impairment is variable
among different patients: while in someMYH9-RD subjects
the hearing defect is mild or moderate even at advanced
age, in other patients hearing loss presents during child-
hood and progresses to profound deafness within the first
decades of life [8-10]. Thus, in many MYH9-RD patients
deafness greatly contributes to patients’ disability.
Non-muscle myosin-IIA is a cytoplasmic myosin
expressed in most cell types and tissues, including the
inner ear [11-14]. As all conventional myosins, it has
a hexameric structure formed by one heavy chain
(NMMHC-IIA) dimer and two pairs of light chains. Each
NMMHC-IIA molecule recognizes an N-terminal head
domain (HD) responsible for enzymatic activity and a C-
terminal tail domain (TD) mainly responsible for myosin
assembly [15]. Genotype-phenotype studies showed that
patients with mutations in the HD have a higher risk of
early-onset and severe deafness than subjects with mu-
tations in the TD [8-10]. Of note, the MYH9 gene was
identified as responsible also for a non-syndromic form
of autosomal-dominant deafness, designated DFNA17
(MIM 603622), in two pedigrees carrying the same HD
mutation, p.R705H [12,16].
Cochlear implantation (CI) is a potential option for pa-
tients with MYH9-RD and severe to profound deafness,
however, no consistent data are available about the risk
to benefit ratio of CI in this condition. Reduced platelet
counts of MYH9-RD patients obviously result in an
increased risk of bleeding complications during of after
surgery, and decision to perform CI and peri-operative
management requires the co-operation of the hematologist
with the ENT surgeon. To date, only one patient with a
clinical diagnosis of EPTS who had received CI has been
reported [17]. This patient benefited from CI, but surgery
was complicated by delayed wound healing and subse-
quent severe chronic infection, which were attributed to
the chronic thrombocytopenia and defective tissue repair
due to the impaired NMMHC-IIA function [17]. The effi-
cacy of CI in MYH9-related deafness is made even more
uncertain in view of the discordant results obtained in
non-syndromic deafness DFNA17: members of both the
reported DNFA17 pedigrees received CIs, with good
outcomes in one family and very poor results in the
other one [16,18].
Here we report the clinical outcome of CI in 10 pa-
tients with MYH9-RD and severe to profound deafness.
Our results provide evidence that CI should be offered
to patients affected by this condition.
Patients and methods
This study includes 10 MYH9-RD patients who received
CI between 1987 and 2009 at 8 different ENT centres inThe Netherlands (1 centre/3 patients), Italy (3 centres/3
patients), France, Germany, Greece, and Argentina (1 pa-
tient each) [19-22]. Mutational screening of the MYH9
gene was performed at 3 different institutions by previ-
ously reported methods [19,20]. Immunofluorescence
assay for the identification of NMMHC-IIA leukocyte
inclusions was carried out as previously described [19,23].
Severity of bleeding was graded according to the WHO
bleeding score, except for severity of intraoperative bleed-
ing during CI surgery, which was described according to
Boezaart et al. [24]. Pure tone audiometric examinations
were performed at the different ENT centers by standard
methods. Pure tone average (PTA) was calculated using
air conduction thresholds at 500, 1000, 2000 and 4000 Hz.
Speech discrimination tests were administered at the dif-
ferent ENT centers too. Despite some differences in the
utilized tests, all of them included the assessment of the
percentages of discrimination of words and sentences at a
conversation voice from an open list, which were therefore
used to describe the CI outcomes. Unless otherwise speci-
fied, the speech perception scores are mentioned without
the use of visual support. To describe short-term outcome
of CI, evaluation at 6 or 12 months after switch-on of the
implanted device was reported; for long-term outcome,
evaluation at the last follow-up visit was used. The investi-
gation was approved by the Institutional Review Board of
the IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
All the patients or their legal guardians gave written in-
formed consent for this retrospective study, which was
conducted according to the declaration of Helsinki.
Results
Patients
The main clinical and laboratory features of the 10
enrolled patients are summarized in Table 1. In all the
cases, diagnosis of MYH9-RD based on the findings of
congenital thrombocytopenia, giant platelets, and identi-
fication of pathognomonic NMMHC-IIA leukocyte in-
clusions by immunofluorescence assay [19], and was
confirmed by identification of the causative MYH9 mu-
tation. In 8 cases the mutations affected the HD of
NMMHC-IIA and in two cases the TD. Finally, for 7 pa-
tients the MYH9-RD was transmitted in an autosomal-
dominant manner, while three patients had sporadic
forms deriving from de novo mutations (Table 1). Table 2
reports the management of bleeding risk on the occa-
sions of previous surgery and respective outcomes.
Sensorineural deafness
All the patients had bilateral sensorineural hearing loss
that at diagnosis affected only or predominantly the high
tones and subsequently progressed toward severe to pro-
found deafness involving all frequencies. Mean age at
onset was 16.6 years and speech development was
























1/1 34/F Sporadic p.R702C
(HD)





















3/3 43/M Sporadic p.R702S
(HD)
No/Yes 21/25 2 (easy bruising,
epistaxis)




4/4 72/M AD p.A95D
(HD)
Yes/Yes 70/nd 0 No No History of chronic
otitis media (left ear)
with TM perforation
A
5/5 27/F AD p.D1424Y
(TD)
Yes/Yes 10/80 0 No No None A




No No None B
7/7 12/M AD p.R705H
(HD)
Yes/Yes 96/nd 0 No No None C




No No None C




No No None C
10/8 54/F AD p.D1424N
(TD)
Yes/Yes 39/nd 2 (easy bruising,
menorrhagia)
No No None D
Notes: 1 = age at time of cochlear implant. 2 = NMMHC-IIA domain affected by mutation. 3 = according to WHO bleeding scale: grade 0, no bleeding; grade 1, only
cutaneous bleeding; grade 2, mild blood loss; grade 3, gross blood loss, requiring transfusion; grade 4, debilitating blood loss, retinal or cerebral associated with
fatality. 4 = immunosuppressive treatments (tacrolimus, mycophenolate mofetil, and steroids) for previous kidney transplantation.
Abbreviations: NMMHC-IIA non-muscle myosin heavy chain IIA, HD head domain, TD tail domain, ref. reference, for previously reported patients, AD autosomal-dominant,
CRF chronic renal failure, TM tympanic membrane, nd not determined.
References: A = Pecci et al., [8]. B = Saposnik et al., [20]. C = Verver et al., [21] D = Greinacher et al. [22].
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and the findings at the last available audiometric examin-
ation before CI are reported in Table 3 and Figure 1. Mean
duration of deafness before CI was 24.2 years (range,
7–55), and mean duration of severe deafness (PTA >70 dB
NHL) before CI was 8.0 years (range, 2–22). In all the sub-
jects CI was performed because of poor benefit deriving
from conventional hearing aids: all the patients had an
open list speech recognition score lower than 50% in the
best aided conditions without lip reading.
CI surgery
Nine patients received unilateral CI, whereas patient 5
received a sequential bilateral implantation at the ages of
27 (left) and 28 (right). In all patients preoperative CT
scan and/or MRI showed no anomalies of the temporal
bone at the implanted side. Table 4 reports prophylaxis
for bleeding complications and perioperative bleeding in
each subject. All patients received prophylactic intraven-
ous antibiotics for 1 to 10 days (median, 3 days) and no
infectious episodes were reported. Perisurgery adverseevents occurred in two patients. In patient 8, a small
hematoma was found at the site of the surgical wound.
One stitch was then removed and by giving pressure the
hematoma was drained without any further complica-
tions. In patient 9, cochleostomy was complicated by
massive gusher that was treated by placing a lumbal
drain and application of gelfoam at the cochleostomy.
Nevertheless, all the electrodes could be correctly in-
troduced. Moreover, postoperatively she developed an
eardrum perforation for which a myringoplasty was
successfully performed. Finally, normal wound healing
was reported for all the patients.
Outcome of CI
Mean follow-up after CI was 9.3 years (range: 1–25).
Table 5 summarizes the results of speech perception
tests administered 6 or 12 months after the switch-on of
the device and at the last follow-up evaluation. The
overall clinical outcome of the CI in the 10 patients can
be summarized as follows. (i) Eight patients obtained
excellent short-term results, with restoration of a practically





Type of surgery Prophylaxis for bleeding Perioperative bleeding
(WHO grade)
1/1 8/14 Kidney transplantations (twice),
nephrectomy, laparotomy (peritonitis)
Platelet transfusions before surgery,
on all interventions
None
2/2 24/31 Splenectomy Platelet transfusions None
3/3 21/25 Tonsillectomy, splenectomy,
removal of pilonidal cyst
Platelet transfusions before surgery,
on all interventions except tonsillectomy
Bleeding after
tonsillectomy (2)
4/4 70/nd None - -
5/5 10/75 None - -
6/6 19/nd Amygdalectomy, removal of
tympanic glomus tumor, reduction
of calcaneous fracture, ankle
arthrodesis, amygdalectomy
Platelet transfusions before surgery,
on all interventions
None
7/7 96/nd Positioning of ventilation tubes None None
8/7 115/nd Appendectomy, ovariectomy, laparoscopic
removal of adhesions, episiotomy
None Bleeding after
episiotomy (2)
9/7 142/nd Fixation of ankle fracture None None
10/8 45/nd Adenoidectomy, nasal septoplasty,
hysterectomy
Tranexamic acid before and
after surgery, on all interventions
None
Abbreviations: nd = not determined.
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evaluation at 6–12 months. For seven of them, this per-
formance was maintained unchanged until the last follow-
up examination carried out at 1 to 9 years after CI (mean,
4.6). For patient 5, such an excellent performance was
maintained for about 10 years. Subsequently, she experi-
enced a progressive deterioration of her hearing ability and
speech perception. Unfortunately, the specific reasons for
this deterioration of CI performance could not be clarified,
as the patient refused any further investigations. (ii) PatientTable 3 Age at onset, progression, and severity of


















1/1 20 23 24 34 87/82
2/2 20 30 32 40 115/120
3/3 8 34 34 43 91/110
4/4 17 64 70 72 107/106
5/5 20 25 25 27 78/91
6/6 25 48 48 50 118/116
7/7 3 5 8 12 97/104
8/7 4 13 19 30 121/111
9/7 19 21 24 46 126/121
10/8 30 33 44 54 100/85
Mean (SD) 16.6 (9) 29.6 (17) 32.8 (17) 40.8 (16)
Notes: 1 = self-reported. 2 = the respective audiometric tracings are showed
in Figure 1.9 obtained worse short-term results with respect to the ma-
jority of other responders (Table 5). However, her ability in
speech discrimination progressively increased over time,
until reaching a maximum sentence score without visual
support of 94% at 13 years follow-up (contextual word
score 50%), and a maximum word score of 64% at 17 years
follow-up (sentence score 85%). However, about 13 years
after CI, she developed a progressive cognitive defect due
to Alzheimer disease that probably affected the results of
speech perception tests and the standard follow-up had
to be stopped for severe dementia 19 years after CI. (iii)
Patient 6 experienced no significant short- or long-term
improvement of hearing ability after CI. On the last evalu-
ation, this patient was able to discriminate 66% and 85% of
words (open and closed list, respectively) and 100% of sen-
tences by lip reading and CI, that was a better performance
than by lip reading alone (data not shown), suggesting that
CI brought some additional information to her. However,
her recognition score was 0% for both words and sentences
by using the CI alone. The subsequent examinations did
not identify a definite cause for this poor outcome.
Discussion
Patients affected by MYH9-RD with severe to profound
deafness are potential candidates for CI. To date the
only information about outcome of this procedure in
MYH9-RD derives from a single case report. This sub-
ject benefited from CI, but surgery was complicated
by delayed wound healing attributed to the chronic
thrombocytopenia and/or NMMHC-IIA dysfunction.
Moreover, the effectiveness of CI in MYH9-related deaf-
ness was questioned in view of the discordant results
Figure 1 (See legend on next page.)
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Figure 1 Audiometric tracings prior to CI in 10 patients with MYH9-RD. Each audiogram reports the air conduction hearing thresholds of
the analyzed patients. Patients are identified by numbers on top right, which correspond to identification numbers reported in Tables. Hearing
threshold is defined as the minimum sound intensity (presented at different frequencies) that can be still perceived by the individual during the
audiometric examination. Hearing thresholds were measured in decibel hearing level (dB HL) and frequencies ranged from 0.25 to 8 kHz. The right ear
is indicated by the red symbol “O” and the left ear by the blue symbol “X”. Severe deafness is defined by mean hearing thresholds worse than 70 dB
HL, profound deafness by mean hearing thresholds worse than 90 dB HL. Arrows indicate hearing thresholds worse than 120 dB HL.
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ness DFNA17 [25]. In order to provide consistent infor-
mation on the risk to benefit ratio of CI in MYH9-RD,
we have gathered the data of 10 patients who received
CI at 8 different institutions.
CI was effective in improving the hearing ability in 9
out of 10 MYH9-RD patients, while one subject did not
take advantage from the procedure. In particular, 8 re-
sponders obtained excellent performances, with restor-
ation of a practically regular hearing function since
evaluation at 6–12 months after the switch-on of the im-
plant. All of them referred restoration of the ability to
engage in a normal conversation even in a noisy envir-
onment; they also reported good performance with
phone conversations or listening to devices such as
radio or television. These excellent responders were
characterized by durations of severe deafness prior to
CI ranging from 2 up to 11 years (mean, 7.0 years).
Moreover, CI performance was similarly good in pa-
tients with different total durations of deafness before
CI (7 to 55 years) and with different ages at implant-










Digisonic SP (Neurelec) P
2/2 R Round
window
Nucleus CI24RE (Cochlear) P
3/3 L Round
window






5/5 L + R Cochleostomy Nucleus Mini22 (Cochlear) n
6/6 L Round
window
Digisonic SP (Neurelec) P
p
7/7 L Cochleostomy Nucleus CI512 (Cochlear) N
8/7 R Cochleostomy Nucleus CI24R (CA) (Cochlear) N
9/7 L Cochleostomy Mini-system 22 CI22M (Cochlear) N
10/8 R Round
window
Maestro Concerto Flex 28 (Med-el) T
1
Notes: 1 = use of cochleostomy or round window for positioning of the device. 2 = B
suction. Grade 2: slight bleeding, infrequent suction. Grade 3: brisk bleeding, freque
removal of suction before instrument can perform manoeuver; Grade 5: uncontrolle
Abbreviations: pre = preoperative, post = postoperatively.performances have been obtained in 6 patients with mu-
tations hitting the HD of NMMHC-IIA or in 2 patients
with mutations in the TD, suggesting that CI outcome
was independent on the specific MYH9 alteration. One
subject (patient 9) benefited from CI, but performance
was not as good as in the other responders. In fact,
results of her speech perception tests were poor at the
short-term evaluation after switch-on; however, her
speech discrimination scores ameliorated over time
until reaching fairly good levels that were maintained
until 17 years after implantation. This patient differed
from the other ones for the markedly longer duration of
severe deafness before CI, i.e. 22 years. In CI responders
affected by other forms of post lingual deafness, dur-
ation of severe deafness prior to implantation was a
major predictor of CI performance [26,27]. We there-
fore hypothesize that this feature affected the CI per-
formance also in this subject and we suggest that CI
should be offered to MYH9-RD patients shortly after
they develop criteria for candidacy.
On the other hand, the reasons why the patient 6 did




latelet apheresis, 1U pre + 1U post 1 None
latelet apheresis, 1U pre 3 None
latelet apheresis, 1U pre + 1U post 1 None
one 1 None
d 1 None




one 2 Hematoma at the site
of surgical wound
one 1 None
ranexamic acid 1 g i.v. pre, then
500 mg/day p.o. post for 7 days
1 None
leeding score adapted according to Boezaart et al., [24]: Grade 1: minimal
nt suction. Grade 4: strong bleeding, bleeding covers surgical field after
d bleeding, bleeding out of mastoid cavity on removal of suction.
Table 5 Results of speech discrimination tests administered 6 or 12 months after the switch-on of the device
(short-term outcome) and at the last follow-up evaluation (long-term outcome) in 10 MYH9-RD patients
Patient/
family











1/1 90 (88) 95 (95) 5 100 (95) 100 (100)
2/2 90 (nd) 90 (nd) 4.5 92 (nd) 90 (nd)
3/3 95 (90) 95 (95) 4.5 98 (97) 100 (100)
4/4 80 (nd) 100 (nd) 5 90 (nd) 100 (nd)
5/5 90 (nd) 98 (nd) 25 nd nd
6/6 0 (0) 0 (0) 17 0 (0) 0 (0)
7/7 97 (88) 100 (nd) 3 100 (85) 100 (nd)
8/7 90 (75) 99 (nd) 9 nd (85)2 nd (100)2
9/7 4 (nd) 24 (nd) 19 nd (42)2 nd (65)2
10/8 95 (nd) 82 (nd) 1 100 (nd) 82 (nd)
Notes: 1 = whenever recorded, results obtained without the contralateral external hearing aid (HA) are reported in parentheses (−HA). 2 = At the time of their
last follow-up evaluations, patients 8 and 9 did not usually utilize a hearing aid: therefore, they were tested with CI alone. Abbreviations: CI = cochlear implant,
nd = not determined.
The speech perception scores are intended without the use of visual support.
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[26,28,29], we could not identify any feature of this pa-
tient explaining her poor response. The patient carried
the p.R33W mutation of the HD of NMMHC-IIA, which
represents a rare variant described in only one other
MYH9-RD patient [30]. However, the clinical pictures of
both patients with p.W33R do not suggest that this
mutation induces a particularly severe NMMHC-IIA
dysfunction with respect to other HD mutations.
CI surgery was carried out without major bleeding
complications. In 4 cases with severe thrombocytopenia,
bleeding risk was managed by prophylactic transfusion
of 1–2 apheresis platelet concentrates. One center with
experience in the care of MYH9-RD patients routinely
uses tranexamic acid to prepare for surgery patients with
moderate thrombocytopenia [31], and successfully used
this drug for prophylaxis of patient 10. In 4 patients with
automated platelet counts ranging from 70 to 129 × 109/L
prophylaxis for bleeding was not deemed necessary. On
the whole, intraoperative bleeding was minimal in 8 pa-
tients and moderate in two cases; no postoperative bleed-
ings occurred, with the exception of the formation, in one
patient, of a hematoma at the site of surgical wound,
which was drained by removing one stitch without any
clinically relevant consequences. In clinical practice, two
aspects should be considered for management of peri-
operative bleeding risk of MYH9-RD patients. First,
routine automated cell counters usually underestimate
platelet counts of these patients. In fact, electronic in-
struments identify platelets mainly based on their size
and fail to recognize very large platelets typical of
MYH9-RD [32]. Thus, microscopic counting should be
used to assess the actual platelet counts of MYH9-RDpatients for their proper management. Secondly, since
in vitro platelet function in MYH9-RD is normal or
only slightly reduced, the indication for prophylactic
transfusions can be reasonably based on the general
recommendations for thrombocytopenias. Recent guide-
lines recommend prophylaxis for patients with platelet
counts below 100 × 109/L before surgery at critical sites,
and this threshold should be considered for CI [33]. On
another line, none of the patients experienced complica-
tions related to delayed wound healing. It is therefore
unlike that the complications observed in the previously
reported MYH9-RD patient who received CI were
dependent on factors specific to the disease [17]. Finally,
three of our patients had conditions leading to increased
risk of infection that are rather frequent among MYH9-RD
patients [3]: two patients had been splenectomized because
of a previous misdiagnosis with immune thrombocytopenia
and one patient was on immunosuppressive treatment
after kidney transplantation. None of them experienced
infectious complications after administration of standard
antimicrobial prophylaxis. We therefore conclude that CI
is a safe procedure in MYH9-RD patients whenever
adequate prophylactic interventions are carried out.
Pathogenesis of MYH9-related deafness is still unclear.
Studies on mouse inner ear showed that NMMHC-IIA
is extensively localized in the hair cells of the organ of
Corti, the spiral ligament and the spiral limbus, with only
minimal expression within the spiral ganglion [12,13]. In
hair cells, NMMHC-IIA is abundantly expressed in ste-
reocilia [14]. Given that CI bypasses hair cells by directly
stimulating the spiral ganglion, the finding that most
MYH9-RD patients have excellent CI performances is
consistent with the NMMHC-IIA expression pattern
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mutations primarily damage the hair cells. Altogether,
these observations strengthen the notion that CI out-
come is better in patients with deafness caused by de-
fects of genes primarily expressed in the hair cells/
membranous labyrinth as opposed to mutations causing
spiral ganglion pathology [25,34], and further point out
the importance of genetic testing in CI candidates. The
introduction of massively parallel sequencing technology
led to recent development of approaches for an efficient
screening of all known deafness genes simultaneously
[35-37]. The identification of definite correlations between
genotype and CI outcome will pave the road to a tailored
patients’ management and reduce the likelihood of inef-
fective CIs and unnecessary costs in healthcare.Conclusions
This study provides evidence that CI is safe and highly
effective in restoring hearing ability in most patients
with MYH9-RD and severe to profound deafness. This
procedure should therefore be offered to these subjects,
possibly as soon as they develop the criteria for candidacy.
Abbreviations
MYH9-RD: MYH9-related disease; NMMHC-IIA: Non-muscle myosin heavy
chain IIA; CI: Cochlear implantation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contibutions
AP designed the research, acquired data, analyzed and interpreted data, and
drafted the manuscript. EJJV, NS, PC, CMB, HP, EK, MB, and VT acquired data,
analyzed and interpreted data, and critically revised the manuscript. AG
designed research, analyzed and interpreted data, and drafted the manuscript.
All the authors revised and accepted the final version of the manuscript.
Acknowledgements
The following physicians contributed to collection of data of the reported
patients: Dr. Paula G. HELLER, Dept. of Hematology Research, Instituto de
Investigaciones Médicas Alfredo Lanari, UE IDIM-CONICET, University of Buenos
Aires, Argentina; Dr. Nathalie TRILLOT, Institut d’Hématologie-Transfusion, Pôle
Biologie Pathologie Génétique, CHRU LILLE, France; Dr. Dorothée DOUCHEMENT,
Service d’Otologie et Otoneurologie, Hôpital Salengro, CHRU LILLE, France.
The research was supported by a grant from the IRCCS Policlinico San
Matteo Foundation to AP.
Author details
1Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation
and University of Pavia, Piazzale Golgi, 27100 Pavia, Italy. 2Department of
Otorhinolaryngology and Head & Neck Surgery, Rudolf Magnus Institute of
Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands.
3Service d’Hématologie Biologique and National Reference Center on
Inherited Platelet Disorders, Robert-Debré Hospital, Paris, France.
4Department of Otorhinolaryngology, IRCCS Policlinico San Matteo
Foundation and University of Pavia, Pavia, Italy. 5Department of
Otorhinolaryngology, Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina. 6Haemophilia Centre and Haemostasis Unit, Aghia Sophia
Children’s Hospital, Athens, Greece. 7Department of Otorhinolaryngology,
Head and Neck Surgery, Ludwig-Maximilian-University, Munich, Germany.
8Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt-Universität,
Greifswald, Germany.Received: 6 May 2014 Accepted: 19 June 2014
Published: 30 June 2014References
1. Kelley MJ, Jawien W, Ortel TL, Korczak JF: Mutation of MYH9, encoding
non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet
2000, 26:106–108.
2. Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, Ghiggeri GM,
Ravazzolo R, Savino M, Del Vecchio M, d’Apolito M, Iolascon A, Zelante LL,
Savoia A, Balduini CL, Noris P, Magrini U, Belletti S, Heath KE, Babcock M,
Glucksman MJ, Aliprandis E, Bizzaro N, Desnick RJ, Martignetti JA: Mutations
in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian
syndromes The May-Hegglin/Fechtner Syndrome Consortium. Nat Genet
2000, 26:103–105.
3. Balduini CL, Pecci A, Savoia A: Recent advances in the understanding and
management of MYH9-related inherited thrombocytopenias. Br J
Haematol 2011, 154:161–174.
4. Pecci A, Biino G, Fierro T, Bozzi V, Mezzasoma A, Noris P, Ramenghi U,
Loffredo G, Fabris F, Momi S, Magrini U, Pirastu M, Savoia A, Balduini C,
Gresele P, Italian Registry for MYH9-releated diseases: Alteration of liver
enzymes is a feature of the MYH9-related disease syndrome. PLoS One
2012, 7:e35986.
5. Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, Nigro A, Noris P,
Gangarossa S, Rocca B, Gresele P, Bizzaro N, Malatesta P, Koivisto PA, Longo
I, Musso R, Pecoraro C, Iolascon A, Magrini U, Rodriguez Soriano J, Renieri A,
Ghiggeri GM, Ravazzolo R, Balduini CL, Savoia A: MYH9-related disease:
May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and
Epstein syndrome are not distinct entities but represent a variable
expression of a single illness. Medicine (Baltimore) 2003, 82:203–215.
6. Althaus K, Greinacher A: MYH-9 Related Platelet Disorders: Strategies for
Management and Diagnosis. Transfus Med Hemother 2010, 37:260–267.
7. Kunishima S, Saito H: Advances in the understanding of MYH9 disorders.
Curr Opin Hematol 2010, 17:405–410.
8. Pecci A, Klersy C, Gresele P, Lee KJ, De Rocco D, Bozzi V, Russo G, Heller PG,
Loffredo G, Ballmaier M, Fabris F, Beggiato E, Kahr WH, Pujol-Moix N,
Platokouki H, Van Geet C, Noris P, Yerram P, Hermans C, Gerber B,
Economou M, De Groot M, Zieger B, De Candia E, Fraticelli V,
Kersseboom R, Piccoli GB, Zimmermann S, Fierro T, Glembotsky AC,
et al: MYH9-Related Disease: A Novel Prognostic Model to Predict the
Clinical Evolution of the Disease Based on Genotype-Phenotype
Correlations. Hum Mutat 2014, 35:236–247.
9. Sekine T, Konno M, Sasaki S, Moritani S, Miura T, Wong WS, Nishio H,
Nishiguchi T, Ohuchi MY, Tsuchiya S, Matsuyama T, Kanegane H, Ida K,
Miura K, Harita Y, Hattori M, Horita S, Igarashi T, Saito H, Kunishima S:
Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations
develop progressive proteinuric renal disease. Kidney Int 2010, 78:207–214.
10. De Rocco D, Zieger B, Platokouki H, Heller PG, Pastore A, Bottega R, Noris P,
Barozzi S, Glembotsky AC, Pergantou H, Balduini CL, Savoia A, Pecci A:
MYH9-related disease: five novel mutations expanding the spectrum of
causative mutations and confirming genotype/phenotype correlations.
Eur J Med Genet 2013, 56:7–12.
11. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR: Non-muscle myosin
II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol
2009, 10:778–790.
12. Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, Castelein CM, Mhatre AN:
Human nonsyndromic hereditary deafness DFNA17 is due to a mutation
in nonmuscle myosin MYH9. Am J Hum Genet 2000, 67:1121–1128.
13. Mhatre AN, Li Y, Atkin G, Maghnouj A, Lalwani AK: Expression of Myh9 in
the mammalian cochlea: localization within the stereocilia. J Neurosci Res
2006, 84:809–18.
14. Lalwani AK, Atkin G, Li Y, Lee JY, Hillman DE, Mhatre AN: Localization in
stereocilia, plasma membrane, and mitochondria suggests diverse roles
for NMHC-IIa within cochlear hair cells. Brain Res 2008, 1197:13–22.
15. Eddinger TJ, Meer DP: Myosin II isoforms in smooth muscle:
heterogeneity and function. Am J Physiol Cell Physiol 2007, 293:C493–508.
16. Hildebrand MS, de Silva MG, Gardner RJ, Rose E, de Graaf CA, Bahlo M, Dahl HH:
Cochlear implants for DFNA17 deafness. Laryngoscope 2006, 116:2211–2215.
17. Nishiyama N, Kawano A, Kawaguchi S, Shirai K, Suzuki M: Cochlear
implantation in a patient with Epstein syndrome. Auris Nasus Larynx 2013,
40:409–412.
Pecci et al. Orphanet Journal of Rare Diseases 2014, 9:100 Page 9 of 9
http://www.ojrd.com/content/9/1/10018. Lalwani AK, Linthicum FH, Wilcox ER, Moore JK, Walters FC, San
Agustin TB, Mislinski J, Miller MR, Sinninger Y, Attaie A, Luxford WM:
A five-generation family with late-onset progressive hereditary
hearing impairment due to cochleosaccular degeneration. Audiol
Neurootol 1997, 2:139–154.
19. Savoia A, De Rocco D, Panza E, Bozzi V, Scandellari R, Loffredo G, Mumford
A, Heller PG, Noris P, De Groot MR, Giani M, Freddi P, Scognamiglio F,
Riondino S, Pujol-Moix N, Fabris F, Seri M, Balduini CL, Pecci A: Heavy chain
myosin 9-related disease (MYH9-RD): neutrophil inclusions of myosin-9
as a pathognomonic sign of the disorder. Thromb Haemost 2010,
103:826–832.
20. Saposnik B, Binard S, Fenneteau O, Nurden A, Nurden P, Hurtaud-Roux MF,
Schlegel N, on behalf of the French MYH9 network: Mutation spectrum
and genotype-phenotype correlations in a large French cohort of
MYH9-related disorders. Mol Genet Genomic Med 2014. in press.
21. Verver E, Pecci A, De Rocco D, Ryhänen S, Barozzi S, Kunst H, Topsakal V,
Savoia A: R705H mutation of MYH9 is associated with MYH9-related
disease and not only with non-syndromic deafness DFNA17. Clin Genet
2014. [Epub ahead of print].
22. Greinacher A, Nieuwenhuis HK, White JG: Sebastian platelet syndrome: a
new variant of hereditary macrothrombocytopenia with leukocyte
inclusions. Blut 1990, 61:282–8.
23. Kunishima S, Matsushita T, Kojima T, Sako M, Kimura F, Jo EK, Inoue C,
Kamiya T, Saito H: Immunofluorescence analysis of neutrophil nonmuscle
myosin heavy chain-A in MYH9 disorders: association of subcellular
localization with MYH9 mutations. Lab Invest 2003, 83:115–122.
24. Boezaart AP, van der Merwe J, Coetzee A: Comparison of sodium
nitroprusside- and esmolol-induced controlled hypotension for functional
endoscopic sinus surgery. Can J Anaesth 1995, 42:373–376.
25. Eppsteiner RW, Shearer AE, Hildebrand MS, Deluca AP, Ji H, Dunn CC,
Black-Ziegelbein EA, Casavant TL, Braun TA, Scheetz TE, Scherer SE, Hansen MR,
Gantz BJ, Smith RJ: Prediction of cochlear implant performance by genetic
mutation: the spiral ganglion hypothesis. Hear Res 2012, 292:51–58.
26. Blamey P, Arndt P, Bergeron F, Bredberg G, Brimacombe J, Facer G, Larky J,
Lindström B, Nedzelski J, Peterson A, Shipp D, Staller S, Whitford L: Factors
affecting auditory performance of postlinguistically deaf adults using
cochlear implants. Audiol Neurootol 1996, 1:293–306.
27. Blamey P, Artieres F, Başkent D, Bergeron F, Beynon A, Burke E, Dillier N,
Dowell R, Fraysse B, Gallégo S, Govaerts PJ, Green K, Huber AM, Kleine-
Punte A, Maat B, Marx M, Mawman D, Mosnier I, O’Connor AF, O’Leary S,
Rousset A, Schauwers K, Skarzynski H, Skarzynski PH, Sterkers O, Terranti A,
Truy E, Van de Heyning P, Venail F, Vincent C: Factors affecting auditory
performance of postlinguistically deaf adults using cochlear implants: an
update with 2251 patients. Audiol Neurootol 2013, 18:36–47.
28. Cohen NL: Cochlear implant candidacy and surgical considerations.
Audiol Neurootol 2004, 9:197–202.
29. Lazard DS, Vincent C, Venail F, Van de Heyning P, Truy E, Sterkers O,
Skarzynski PH, Skarzynski H, Schauwers K, O’Leary S, Mawman D, Maat B,
Kleine-Punte A, Huber AM, Green K, Govaerts PJ, Fraysse B, Dowell R, Dillier
N, Burke E, Beynon A, Bergeron F, Başkent D, Artières F, Blamey PJ: Pre-,
peri- and postoperative factors affecting performance of postlinguistically
deaf adults using cochlear implants: a new conceptual model over time.
PLoS One 2012, 7:e48739.
30. Sun XH, Wang ZY, Yang HY, Cao LJ, Su J, Yu ZQ, Bai X, Ruan CG: Clinical,
pathological, and genetic analysis of ten patients with MYH9-related
disease. Acta Haematol 2013, 129:106–113.
31. Althaus K, Greinacher A: MYH9-related platelet disorders. Semin Thromb
Hemost 2009, 35:189–203.
32. Noris P, Klersy C, Zecca M, Arcaini L, Pecci A, Melazzini F, Terulla V, Bozzi V,
Ambaglio C, Passamonti F, Locatelli F, Balduini CL: Platelet size
distinguishes between inherited macrothrombocytopenias and immune
thrombocytopenia. J Thromb Haemost 2009, 7:2131–2136.
33. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G, Italian Society
of Transfusion Medicine and Immunohaematology (SIMTI) Work Group:
Recommendations for the transfusion of plasma and platelets. Blood
Transfus 2009, 7:132–50.
34. Miyagawa M, Nishio SY, Ikeda T, Fukushima K, Usami S: Massively parallel
DNA sequencing successfully identifies new causative mutations in
deafness genes in patients with cochlear implantation and EAS. PLoS
One 2013, 8:e75793.35. Shearer AE, Black-Ziegelbein EA, Hildebrand MS, Eppsteiner RW, Ravi H, Joshi
S, Guiffre AC, Sloan CM, Happe S, Howard SD, Novak B, Deluca AP, Taylor
KR, Scheetz TE, Braun TA, Casavant TL, Kimberling WJ, Leproust EM, Smith
RJ: Advancing genetic testing for deafness with genomic technology.
J Med Genet 2013, 50:627–634.
36. Shearer AE, DeLuca AP, Hildebrand MS, Taylor KR, Gurrola J 2nd, Scherer S,
Scheetz TE, Smith RJ: Comprehensive genetic testing for hereditary
hearing loss using massively parallel sequencing. Proc Natl Acad Sci USA
2010, 107:21104–21109.
37. Schrauwen I, Sommen M, Corneveaux JJ, Reiman RA, Hackett NJ, Claes C,
Claes K, Bitner-Glindzicz M, Coucke P, Van Camp G, Huentelman MJ: A sensitive
and specific diagnostic test for hearing loss using a microdroplet PCR-based
approach and next generation sequencing. Am J Med Genet A 2013,
161A:145–152.
doi:10.1186/1750-1172-9-100
Cite this article as: Pecci et al.: Cochlear implantation is safe and effective
in patients with MYH9-related disease. Orphanet Journal of Rare Diseases
2014 9:100.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
